Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
5
×
life sciences
national blog main
boston top stories
national top stories
san francisco blog main
san francisco top stories
biotech
boston
deals
new york blog main
new york top stories
startups
biogen
boulder/denver blog main
boulder/denver top stories
cancer
clinical trials
crispr
deerfield management
detroit blog main
detroit top stories
europe blog main
europe top stories
fda
gilead sciences
indiana blog main
indiana top stories
ipo
melinta therapeutics
national
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
sanofi
seattle blog main
seattle top stories
texas blog main
What
bio
5
×
medicines
5
×
ipo
new
covid
deal
diseases
roundup
years
acquisitions
activity
analysis
announced
approvals
bets
biogen
biotech
bring
cancer
ceo
clamped
collabs
comes
companies
company
create
crispr
cut
daniel
date
delays
develop
developing
diagnostic
drug
economic
editing
effective
employing
enticed
Language
unset
Current search:
medicines
×
" boston blog main "
×
bio
×
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
6 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines